19:45 , Nov 6, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays; gene profiling; tissue markers Gene profiling coupled with cell-based assays of patient samples could help predict drug responses in AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Company News

Rasna, Active With Me deal

Rasna reverse-merged with Active With Me. The combined company retained Rasna’s name and will focus on modulating nucleophosmin ( NPM1 ; B23) and lysine-specific demethylase 1 ( LSD1 ; KDM1A ), which it says is...
07:00 , May 19, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) gained $1.85 to $33.22 last week after submitting an NDA to FDA for deoxycholic acid (ATX-101) to reduce submental (under chin) fat. Kythera plans to submit ex-U.S. regulatory applications...
07:00 , May 5, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $3.51 (10%) to $32.39 on Friday after FDA asked for an additional clinical trial in a complete response letter for Plumiaz diazepam nasal spray to treat acute repetitive...
07:00 , Apr 7, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Cubist Pharmaceuticals Inc. (NASDAQ:CBST) was off $1.66 to $68.44 last week after FDA's Anti-Infective Drugs Advisory Committee voted unanimously in favor of approval of Sivextro tedizolid to treat acute bacterial skin and skin...
07:00 , Mar 10, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/7 cls Biogen Idec Inc. (NASDAQ:BIIB) BMO Capital Markets Jim Birchenough Upgrade Outperform (from market perform) -4% $328.75 Birchenough also raised his target to...
08:00 , Nov 25, 2013 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/22 cls Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Canaccord Ritu Baral New Buy 9% $11.64 Baral initiated coverage with a $19 target, saying Aerie's AR-13324 has...
08:00 , Nov 18, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Algeta ASA (OSE:ALGETA) was off NOK4.60 to NOK263.40 on Friday after the European Commission approved an MAA from partner Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat adults with castration-resistant prostate cancer...
07:00 , Oct 28, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Actelion Ltd. (SIX:ATLN) was off CHF0.20 to CHF69.15 on Friday after EMA's CHMP backed approval of Opsumit macitentan for pulmonary arterial hypertension (PAH). Actelion gained CHF4.55 on the week. The move included a...
07:00 , Oct 14, 2013 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/11 cls Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) Barclays Capital Ying Huang Downgrade Underweight (from overweight) -77% $4.26 Brean Capital Jonathan Aschoff Downgrade Hold (from buy)...